Zobrazeno 1 - 10
of 138
pro vyhledávání: '"D. Karalis"'
Autor:
John D. Karalis, Lynn Y. Yoon, Suntrea T. G. Hammer, Changjin Hong, Min Zhu, Ibrahim Nassour, Michelle R. Ju, Shu Xiao, Esther C. Castro‑Dubon, Deepak Agrawal, Jorge Suarez, Scott I. Reznik, John C. Mansour, Patricio M. Polanco, Adam C. Yopp, Herbert J. Zeh III, Tae Hyun Hwang, Hao Zhu, Matthew R. Porembka, Sam C. Wang
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/30bed287feca45c48752907a4b89cd52
Publikováno v:
BioMedInformatics, Vol 4, Iss 2, Pp 1348-1362 (2024)
Background: Allergic contact dermatitis (ACD) is a delayed hypersensitivity reaction occurring in sensitized individuals due to exposure to allergens. Polysensitization, defined as positive reactions to multiple unrelated haptens, increases the risk
Externí odkaz:
https://doaj.org/article/ade47ff1aac249b5a36264b008a80468
Autor:
Vangelis D. Karalis
Publikováno v:
Applied Biosciences, Vol 3, Iss 1, Pp 14-44 (2024)
The purpose of this literature review is to provide a fundamental synopsis of current research pertaining to artificial intelligence (AI) within the domain of clinical practice. Artificial intelligence has revolutionized the field of medicine and hea
Externí odkaz:
https://doaj.org/article/cff9917dd9ea48a5b1e05d320b4f37c7
Autor:
Maria Kokkali, Vangelis D. Karalis
Publikováno v:
Applied Sciences, Vol 14, Iss 14, p 6115 (2024)
Despite ongoing concerns, the primary metric utilized in bioequivalence studies to quantify absorption rate remains the maximum plasma concentration (Cmax). To more accurately depict absorption rate, the concept of “average slope” (AS) has been r
Externí odkaz:
https://doaj.org/article/337b304480b64c3aad9f403519ad7b89
Autor:
Vangelis D. Karalis
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 11, Iss 7, p 185 (2024)
A novel idea is introduced regarding the statistical comparisons of endpoints in clinical trials. Currently, the (dis)similarity of measured endpoints is not assessed. Instead, statistical analysis is directly applied, which can lead to multiplicity
Externí odkaz:
https://doaj.org/article/211480e7a78c468ea396ce464bb945a0
Publikováno v:
Applied Sciences, Vol 14, Iss 12, p 5279 (2024)
The bioequivalence (BE) of highly variable drugs is a complex issue in the pharmaceutical industry. The impact of this variability can significantly affect the required sample size and statistical power. In order to address this issue, the EMA and FD
Externí odkaz:
https://doaj.org/article/811035b5f5a1456f9d8ba6b6c43b0c1c
Publikováno v:
Applied Sciences, Vol 14, Iss 11, p 4570 (2024)
Determining the appropriate sample size is crucial in clinical studies due to the potential limitations of small sample sizes in detecting true effects. This work introduces the use of Wasserstein Generative Adversarial Networks (WGANs) to create vir
Externí odkaz:
https://doaj.org/article/404692b1136445639364fc8f95eca027
Publikováno v:
Applied Sciences, Vol 14, Iss 7, p 2970 (2024)
Sample size is a key factor in bioequivalence and clinical trials. An appropriately large sample is necessary to gain valuable insights into a designated population. However, large sample sizes lead to increased human exposure, costs, and a longer ti
Externí odkaz:
https://doaj.org/article/54a5a5b69e6e4a38b6db35c6deb9726a
Autor:
John D. Karalis, MD, Liwei Jia, MD, PhD, Natia Murvelashvili, MD, Amy Vora, MD, Alex Tessnow, MD, Alan P.B. Dackiw, MD, PhD, MBA
Publikováno v:
AACE Clinical Case Reports, Vol 8, Iss 3, Pp 131-134 (2022)
Objective: Distant metastases from papillary thyroid carcinoma (PTC) are relatively rare and may be associated with a poor prognosis. The adrenal gland is a highly unusual site of metastasis in the natural course of PTC. Herein, we describe a case of
Externí odkaz:
https://doaj.org/article/e483a849c5fd4ca7b208406dd9cd12d4
Autor:
John D. Karalis, Lynn Y. Yoon, Suntrea T. G. Hammer, Changjin Hong, Min Zhu, Ibrahim Nassour, Michelle R. Ju, Shu Xiao, Esther C. Castro-Dubon, Deepak Agrawal, Jorge Suarez, Scott I. Reznik, John C. Mansour, Patricio M. Polanco, Adam C. Yopp, Herbert J. Zeh, Tae Hyun Hwang, Hao Zhu, Matthew R. Porembka, Sam C. Wang
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background Lenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficacy of lenvatinib monot
Externí odkaz:
https://doaj.org/article/eefb831987264d6b88bacc7638ab3ccd